Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Peter, Stella"'
Autor:
Narges Razavian, Vincent J. Major, Mukund Sudarshan, Jesse Burk-Rafel, Peter Stella, Hardev Randhawa, Seda Bilaloglu, Ji Chen, Vuthy Nguy, Walter Wang, Hao Zhang, Ilan Reinstein, David Kudlowitz, Cameron Zenger, Meng Cao, Ruina Zhang, Siddhant Dogra, Keerthi B. Harish, Brian Bosworth, Fritz Francois, Leora I. Horwitz, Rajesh Ranganath, Jonathan Austrian, Yindalon Aphinyanaphongs
Publikováno v:
npj Digital Medicine, Vol 3, Iss 1, Pp 1-13 (2020)
Abstract The COVID-19 pandemic has challenged front-line clinical decision-making, leading to numerous published prognostic tools. However, few models have been prospectively validated and none report implementation in practice. Here, we use 3345 ret
Externí odkaz:
https://doaj.org/article/24a1e6844b2b4deb962b0c15b73995db
Autor:
Nicole M Adler, Leora I Horwitz, Yindalon Aphinyanaphongs, Ben Zhang, Keerthi Harish, Peter Stella, Kevin Hauck, Marwa M Moussa
Publikováno v:
BMJ Health & Care Informatics, Vol 28, Iss 1 (2021)
Objectives Predictive studies play important roles in the development of models informing care for patients with COVID-19. Our concern is that studies producing ill-performing models may lead to inappropriate clinical decision-making. Thus, our objec
Externí odkaz:
https://doaj.org/article/6cc579ecb684476bb6d41b2680054091
Autor:
Peter Stella
Publikováno v:
Journal of Applied Corporate Finance. 33:8-23
Autor:
Jean-François Yale, Jeremy Hodson Pettus, Miguel Brito-Sanfiel, Fernando Lavalle-Gonzalez, Ana Merino-Trigo, Peter Stella, Soazig Chevalier, Raffaella Buzzetti
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190579 (2018)
To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs.A po
Externí odkaz:
https://doaj.org/article/8a5e9a7e1ac64e8eb639da9f0c475957
Publikováno v:
AMIA Annu Symp Proc
Pediatric sepsis imposes a significant burden of morbidity and mortality among children. While the speedy application of existing supportive care measures can substantially improve outcomes, further improvements in delivering that care require tools
Autor:
David Kudlowitz, Cameron Zenger, Meng Cao, Ruina Zhang, Fritz Francois, Ilan Reinstein, Brian P. Bosworth, Mukund Sudarshan, Walter Wang, Vincent J. Major, Hao Zhang, Siddhant Dogra, Ji Chen, Jesse Burk-Rafel, Narges Razavian, Yindalon Aphinyanaphongs, Hardev Randhawa, Leora I. Horwitz, Jonathan S. Austrian, Vuthy Nguy, Rajesh Ranganath, Seda Bilaloglu, Peter Stella, Keerthi B. Harish
Publikováno v:
npj Digital Medicine, Vol 3, Iss 1, Pp 1-13 (2020)
NPJ Digital Medicine
npj Digital Medicine
NPJ Digital Medicine
npj Digital Medicine
The COVID-19 pandemic has challenged front-line clinical decision-making, leading to numerous published prognostic tools. However, few models have been prospectively validated and none report implementation in practice. Here, we use 3345 retrospectiv
Publikováno v:
Diabetes Therapy
Introduction OPTIMIZE evaluated the efficacy, safety and treatment satisfaction of insulin glargine 300 U/mL once daily (Gla-300 OD) in people with type 1 diabetes mellitus (T1DM) previously uncontrolled on basal insulin twice daily (BID) as part of
Autor:
Zijie J. Wang, Alex Kale, Harsha Nori, Peter Stella, Mark E. Nunnally, Duen Horng Chau, Mihaela Vorvoreanu, Jennifer Wortman Vaughan, Rich Caruana
Machine learning (ML) interpretability techniques can reveal undesirable patterns in data that models exploit to make predictions--potentially causing harms once deployed. However, how to take action to address these patterns is not always clear. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8e96183869b4a40fc870bce5dd0f96d
Autor:
Aramesh Saremi, Francisco J. Tinahones, Pablo Aschner, Adam G. Tabak, Juris J. Meier, Peter Stella, Carol Wysham, John E Anderson, Minzhi Liu
Publikováno v:
Diabetes Therapy
Introduction Basal-bolus (BB) regimens are generally used to intensify basal insulin therapy in patients with type 2 diabetes (T2D) not meeting glycemic targets. However, drawbacks include multiple injection burden and risk of weight gain and hypogly
Publikováno v:
Diabetes. 70
Background: Currently no data are available on the real-world effectiveness of the fixed ratio combination of insulin glargine 100 U/ml and lixisenatide (iGlarLixi). This non-interventional study (it was conducted in Hungary) aimed to evaluate its ef